Xarelto revenue trends
In 3Q17, Johnson & Johnson’s (JNJ) Xarelto generated revenues of $635 million, a ~20% increase on a year-over-year (or YoY) basis and a 1% decline quarter-over-quarter.
Xarelto saw year-to-date September 2017 revenues of $1.8 billion compared to $1.7 billion in YTD (year-to-date) September 2016.
Xarelto (rivaroxaban) is used to decrease the risk of stroke and systemic embolism in individuals with nonvalvular atrial fibrillation. Xarelto is also used for the treatment of deep vein thrombosis and pulmonary embolism.
In December 2017, Johnson & Johnson submitted a supplemental new drug application (or sNDA) to the US Food and Drug Administration (or FDA) for the expansion of indications for Xarelto. Johnson & Johnson submitted the sNDA to include Xarelto as a treatment for diminishing the risk of major cardiovascular events such as cardiovascular death, heart attack, or stroke in individuals with chronic coronary or peripheral artery disease. Johnson & Johnson’s sNDA also includes Xarelto for the reduction of the risk of acute limb ischemia in individuals with pulmonary arterial disorder.
Johnson & Johnson’s sNDA is based on the results of the phase three COMPASS trial. In the COMPASS trial, Xarelto 2.5mg vascular dose demonstrated a reduction in the risk of cardiovascular events, heart attack, and stroke by 24% compared to patients on aspirin alone.
Xarelto competes with Bristol-Myers Squibb (BMY) and Pfizer’s (PFE) Eliquis (apixaban) Boehringer Ingelheim’s Pradaxa, and Portola Pharmaceuticals’ (PTLA) Bevyxxa. The revenue growth of JNJ’s Xarelto could boost the share prices of the Pharmaceutical ETF (PPH). Johnson & Johnson makes up about ~5.1% of PPH’s total portfolio holding.